0001415889-24-019462.txt : 20240710
0001415889-24-019462.hdr.sgml : 20240710
20240710161128
ACCESSION NUMBER: 0001415889-24-019462
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240708
FILED AS OF DATE: 20240710
DATE AS OF CHANGE: 20240710
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Leyman Barbara
CENTRAL INDEX KEY: 0002028309
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38662
FILM NUMBER: 241110098
MAIL ADDRESS:
STREET 1: C/O SUTRO BIOPHARMA, INC.
STREET 2: 111 OYSTER POINT BOULEVARD
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: SUTRO BIOPHARMA, INC.
CENTRAL INDEX KEY: 0001382101
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 452441988
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 111 OYSTER POINT BLVD.
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650-392-8412
MAIL ADDRESS:
STREET 1: 111 OYSTER POINT BLVD.
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
FORMER COMPANY:
FORMER CONFORMED NAME: SUTRO BIOPHARMA INC
DATE OF NAME CHANGE: 20061127
4
1
form4-07102024_080725.xml
X0508
4
2024-07-08
0001382101
SUTRO BIOPHARMA, INC.
STRO
0002028309
Leyman Barbara
C/O SUTRO BIOPHARMA, INC.
111 OYSTER POINT BOULEVARD
SOUTH SAN FRANCISCO
CA
94080
false
true
false
false
Chief Business Dev. Officer
0
Stock Option (Right to Buy Common Stock)
3.04
2024-07-08
4
A
0
125000
0
A
2034-07-08
Common Stock
125000
125000
D
Restricted Stock Units (RSUs)
2024-07-08
4
A
0
100000
0
A
2028-07-08
Common Stock
100000
100000
D
The option vests as to 25% of the total award on July 8, 2025, then in equal monthly installments over the following three years, subject to the reporting person's continued service to the issuer on each vesting date.
Each RSU represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement.
The RSUs vest as to 1/4th of the total award annually beginning on July 8, 2025, subject to the reporting person's continued service to the issuer through each vesting date.
/s/ Edward C. Albini as attorney-in-fact for Barbara Leyman
2024-07-10